AMCIHIGH SIGNALFINANCIAL10-K

AMCI appears to be a SPAC that terminated its original business combination and is seeking a new target while extending its deadline to April 2025.

The company terminated its planned merger with Wanshun in March 2024 and has since deposited $880,000 into trust to extend the business combination deadline to April 2025. The transfer of founder shares to Peace Capital Limited and the ongoing search for a new target creates uncertainty about the ultimate outcome for shareholders.

Comparing 2025-04-14 vs 2024-04-16View on EDGAR →
FINANCIAL ANALYSIS

The company experienced a meaningful decline in revenue and substantially reduced R&D expenses, while operating losses improved modestly. Total assets decreased by over one-third, with notable reductions in inventory and current liabilities, suggesting operational contraction following the terminated business combination. The overall financial picture reflects a SPAC in transition, with reduced operational activity as it seeks a new merger target.

FINANCIAL STATEMENT CHANGES
R&D Expense
P&L
-77.3%
$255K→$58K

R&D spending cut 77.3% — could signal cost discipline or concerning reduction in innovation investment.

Inventory
Balance Sheet
-69.9%
$3.6M→$1.1M

Inventory drawn down 69.9% — strong sell-through or deliberate destocking; watch for supply constraints.

Current Liabilities
Balance Sheet
-60.8%
$1.8M→$687K

Current liabilities reduced — improved short-term financial position and working capital health.

Total Liabilities
Balance Sheet
-57.4%
$1.8M→$746K

Liabilities reduced 57.4% — deleveraging improves balance sheet strength and financial flexibility.

Operating Income
P&L
+42%
-$871K→-$505K

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Revenue
P&L
-41.4%
$10.2M→$6.0M

Revenue declined 41.4% — significant demand weakness or market share loss warrants investigation.

Total Assets
Balance Sheet
-38.1%
$18.1M→$11.2M

Total assets contracted 38.1% — asset sales, write-downs, or balance sheet optimization underway.

LANGUAGE CHANGES
NEW — 2025-04-14
PRIOR — 2024-04-16
ADDED
As of April 14, 2025, there were 3,854,856 ordinary shares, par value $ 0.0001 issued and outstanding.
On February 7, 2022, our AlphaVest Holding, LP (our Sponsor ) acquired 1,725,000 Ordinary Shares (the Founders Shares ) for an aggregate purchase price of $25,000, which represented 20% of our issued and outstanding shares after our initial public offering (as defined below).
On April 18, 2023, the Sponsor transferred an aggregate of 1,035,000 Founder Shares to Peace Capital Limited.
Also on December 21, 2023, the Company entered into a non-interest bearing promissory note with the Sponsor for $165,000, which was used to fund the first extension.
The Company subsequently exercised the remaining nine one-month extensions by depositing $55,000 per one-month extension into the Trust Account, extending the deadline to complete the business combination to December 22, 2024.
As of the date of this filing, an aggregate of $880,000 was deposited into trust account to extend the business combination period to April 22, 2025.
Since our IPO, our sole business activity has been identifying and evaluating suitable acquisition transaction candidates.
Facilities We currently maintain our executive offices at 205 W.
As of December 31, 2024, we had a working capital deficiency of $1,745,636.
As a result, in addition to our Initial Shareholders Founder Shares, we would do not need any of the 3,854,856 public shares outstanding to be voted in favor of an initial business combination in order to have our initial business combination approved (assuming all outstanding shares are voted and the EBC Founder Shares are voted in favor of a business combination).
REMOVED
As of April 16, 2024, there were 7,006,329 ordinary shares, par value $0.0001 issued and outstanding.
On February 7, 2022, our AlphaVest Holding, LP (our Sponsor ) acquired 1,725,000 founder shares for an aggregate purchase price of $25,000, which represents 20% of our issued and outstanding shares after our initial public offering (as defined below).
On March 18, 2024, the Company delivered to Wanshun a Notice of Termination of Business Combination (the Termination ), in which the Business Combination Agreement was terminated pursuant to Section 8.1(e) of the Business Combination Agreement.
The termination of the Business Combination Agreement is effective as of March 18, 2024.
Pursuant to Section 8.2(b) of the Business Combination Agreement, Wanshun shall remit a termination fee to Sponsor as soon as reasonably practicable.
Also on December 21, 2023, the Company entered into a non-interest bearing promissory note with the Sponsor for $165,000 (the Extension Note ), which was used to fund extension payments.
On April 15, 2024, we amended and restated the Extension Note to increase the principal amount to $715,000 and extend the maturity date to the earlier of: (i) September 12, 2024 or (ii) promptly after the date on the consummation of the business combination .
On March 21, 2024, the Company exercised its second extension by depositing $55,000 into the Trust Account to extend the deadline to complete the business combination from March 22, 2024 to April 22, 2024.
Our officers and directors have no prior experience consummating an initial business combination for a blank check company.
5 Facilities We currently maintain our executive offices at 420 Lexington Avenue, Suite 2446, New York NY, 10170.
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →